Mylan N.V. (MYL): Price and Financial Metrics
MYL Stock Summary
- Mylan NV's stock had its IPO on December 18, 1987, making it an older stock than 90.59% of US equities in our set.
- The volatility of Mylan NV's share price is greater than that of merely 5.12% US stocks with at least 200 days of trading history.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MYL comes in at 11.7% -- higher than that of 83.44% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Mylan NV, a group of peers worth examining would be CBT, WAB, PKI, MTX, and ESI.
- MYL's SEC filings can be seen here. And to visit Mylan NV's official web site, go to www.mylan.com.
MYL Stock Price Chart Interactive Chart >
MYL Price/Volume Stats
|Current price||$15.85||52-week high||$23.11|
|Prev. close||$15.55||52-week low||$12.75|
|Day high||$16.15||Avg. volume||6,488,034|
|50-day MA||$15.21||Dividend yield||N/A|
|200-day MA||$16.31||Market Cap||8.58B|
Mylan N.V. (MYL) Company Bio
Mylan NV develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company was founded in 1961 and is based in Potters Bar, Hertfordshire.
MYL Latest News Stream
|Loading, please wait...|
MYL Latest Social Stream
View Full MYL Social Stream
Latest MYL News From Around the Web
Below are the latest news stories about Mylan NV that investors may wish to consider to help them evaluate MYL as an investment opportunity.
Global Reversible Airway Diseases Treatment Market 2020: Covering Competitive Scenario And Dynamics By Mylan N.V., Boehringer Ingelheim International GmbH, Regeneron, Sanofi, Genentech, Inc. (F. HoffmannLa Roche Ltd), Novartis AG
Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Reversible Airway Diseases Treatment Market, By Type (Bronchodilators, Cytotoxic Drugs, Antibiotics, Others), Treatment (Chest X Ray, CT Scan, Lung Therapies, Surgery Transplant and Medications), Diseases
Carboplatin Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026(Fresenius Kabi, Mylan, Qilu)
Los Angeles, United State, – – QY Research recently added a research report, Global Carboplatin Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Carboplatin market. It highlights the drivers and restraints
Drug Addiction Treatment Market Strategic Insights 2020 with analysis of Leading Players: Pfizer, Indivior, Novartis, Alkermes, Cipla, Mylan, Dr. Reddy's Laboratorie, etc.
The Global Drug Addiction Treatment Market research study takes a comprehensive approach towards studying the key trends influencing the growth of this sector. The report comprises data that offers an in-depth insight into the business sector. The research report focuses
Outstanding Growth of Opioids Drug Market is estimated to reach $11.8 Billion by 2025 | International Company’s - J&J, Teva, Mylan, Pfizer, Mallinckrodt
Global Opioids Drug Market Synopsis: The Opioids Drug Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Opioids Drug Market size to maintain the average annual growth rate of 0.83% from $11.1
Calcium Folinate Market 2020: Growing Demand for Efficient Management Observes Report Till 2025 with Merck, Teva, Mylan
The Calcium Folinate market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional
MYL Price Returns
Continue Researching MYLHere are a few links from around the web to help you further your research on Mylan NV's stock as an investment opportunity:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!